文献速递炎症性肠病肝病

妊娠期使用硫唑嘌呤与系统性红斑狼疮及炎症性肠病妊娠合并肝内胆汁淤积症

Thiopurines and Intrahepatic Cholestasis of Pregnancy in Systemic Lupus Erythematosus and Inflammatory Bowel Disease Pregnancies.
PubMed 文献 · Am J Gastroenterol · 2025-07-23

基于瑞典全国医疗登记数据的登记队列研究纳入2007—2022年所有合并系统性红斑狼疮(SLE)或炎症性肠病(IBD)的单胎妊娠,比较妊娠期暴露于硫唑嘌呤或6-巯基嘌呤与否发生肝内胆汁淤积症(ICP)的风险。SLE中暴露组ICP 4.7% vs 匹配未暴露组1.9%(校正RR 3.06,95%CI 1.36-6.90);IBD中暴露组7.3% vs 匹配未暴露组0.9%(校正RR 7.78,95%CI 5.41-11.17)。作者认为硫嘌呤暴露与ICP风险升高相关。

要点

  • SLE妊娠中硫嘌呤暴露者ICP发生率为4.7%,匹配未暴露者为1.9%,校正RR 3.06(95%CI 1.36-6.90)。
  • IBD妊娠中硫嘌呤暴露者ICP发生率为7.3%,匹配未暴露者为0.9%,校正RR 7.78(95%CI 5.41-11.17)。
  • 按ICP病史、高血压、肾脏疾病、肝脏疾病、糖皮质激素使用、IBD亚型及硫嘌呤种类所做敏感性及亚组分析结果一致。

核心结论

  • 在SLE与IBD妊娠中,妊娠期硫嘌呤暴露与ICP风险升高相关,且不受ICP病史、高血压、肾脏疾病、肝脏疾病及糖皮质激素使用影响。

研究设计与样本

  • 基于瑞典全国医疗登记数据的登记队列研究。
  • 纳入2007—2022年瑞典所有合并SLE或IBD的单胎妊娠。
  • 暴露定义为从末次月经日期至分娩前1天或ICP诊断前至少1次阿扎硫嘌呤或6-巯基嘌呤配药,对照为无配药。
  • 采用倾向评分匹配(1例硫嘌呤暴露配2例硫嘌呤未暴露),校正母亲吸烟、体重指数、产次、IBD亚型、糖皮质激素及先进疗法等混杂因素。
  • 采用改良泊松模型估计风险比(RR)及95%置信区间(CI)。

主要发现

  • SLE中,硫嘌呤暴露妊娠297例中14例(4.7%)发生ICP,匹配未暴露妊娠594例中11例(1.9%)发生ICP(校正RR 3.06,95%CI 1.36-6.90;校正风险差4%,95%CI 1%-6%)。
  • IBD中,硫嘌呤暴露妊娠1,924例中140例(7.3%)发生ICP,匹配未暴露妊娠3,848例中36例(0.9%)发生ICP(校正RR 7.78,95%CI 5.41-11.17;校正风险差6%,95%CI 5%-8%)。
  • 按ICP病史、孕前高血压、肾脏疾病、肝脏疾病、糖皮质激素使用、IBD亚型及硫嘌呤种类的敏感性及亚组分析,以及妊娠期硫嘌呤与肿瘤坏死因子抑制剂暴露的比较,结果一致。

关键数值与推荐

  • ICP诊断依据住院或门诊诊疗中的ICD-10编码O26.6识别。
  • SLE:暴露组ICP 14/297(4.7%)vs 匹配未暴露组11/594(1.9%),校正RR 3.06(95%CI 1.36-6.90)。
  • IBD:暴露组ICP 140/1,924(7.3%)vs 匹配未暴露组36/3,848(0.9%),校正RR 7.78(95%CI 5.41-11.17)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The objective of this study was to examine the effects of thiopurine exposure during pregnancy on intrahepatic cholestasis of pregnancy (ICP) in systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD) pregnancies using nationwide data from Swedish healthcare registers. METHODS: This register-based cohort study included all singleton pregnancies with prevalent SLE or IBD in Sweden, 2007-2022. Exposure was ≥1 dispensation for azathioprine or 6-mercaptopurine from last menstrual period date to 1 day before delivery or before ICP diagnosis vs no dispensation. ICP diagnosis was identified with ICD-10 code O26.6 in inpatient or outpatient care. Propensity score matching (1 thiopurine-exposed and 2 thiopurine-unexposed) controlled for confounding factors (e.g., maternal smoking, body mass index, parity, IBD subtypes, glucocorticoids, and advanced therapies). Modified Poisson models were used to estimate risk ratios (RRs) and 95% confidence intervals (CIs). RESULTS: In SLE, ICP occurred in 14 of 297 (4.7%) thiopurine-exposed pregnancies vs 11 of 594 (1.9%) matched unexposed pregnancies (adjusted RR 3.06, 95% CI 1.36-6.90; adjusted risk difference 4%, 95% CI 1%-6%). In IBD, ICP developed in 140 of 1,924 (7.3%) exposed pregnancies vs 36 of 3,848 (0.9%) matched unexposed pregnancies (adjusted RR 7.78, 95% CI 5.41-11.17; adjusted risk difference 6%, 95% CI 5%-8%). Sensitivity and subgroup analyses by ICP history, pregestational hypertension, renal diseases, liver diseases, glucocorticoid use, IBD subtypes, and thiopurine substance, and comparing thiopurines with tumor necrosis factor inhibitors exposure during pregnancy provided consistent results. DISCUSSION: In SLE and IBD, thiopurine exposure during pregnancy was associated with an increased risk of ICP, regardless of ICP history, hypertension, renal diseases, liver diseases, and glucocorticoid use.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Nguyen NV, Sandström A, Dominicus A, et al. Thiopurines and Intrahepatic Cholestasis of Pregnancy in Systemic Lupus Erythematosus and Inflammatory Bowel Disease Pregnancies. Am J Gastroenterol. 2025. PMID: 40699247. doi:10.14309/ajg.0000000000003652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。